Oil Refineries Stock (OTC:OILRF), Trade Ideas

Oil Refineries Ltd (ORL), also known as Bazan Group, engages in the production of fuel products. It also manufactures raw materials for the petrochemical industry and materials for the plastic industry, including oils, wax, and accompanying products. The company also provides power and water (mainly electricity and steam) services to a number of industries located near the refinery in Israel. The variety of products refined by ORL is used in industrial operations, transportation, private consumption, agriculture, and infrastructures. ORL plays a key role in Israel's refinery complex, with a major portion of refined products going to local consumption. Although the majority of operations are consumed by refining, ORL is also active in polymer and aromatic production through subsidiaries.

OIL REFRINERIES LTD ORD by Oil Refineries Ltd.

Oil Refineries Ltd

TriCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBK#NASDAQ">TCBK</a>) reported quarterly earnings of $0.83 per share which beat the analyst consensus estimate of $0.80 by 3.75 percent. This is a 22.43 percent decrease over earnings of $1.07 per share from the same period last year. The company reported quarterly sales of $98.507 million which missed the analyst consensus estimate of $100.039 million by 1.53 percent. This is a 7.91 percent decrease over sales of $106.971 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

TCBK

TriCo Q1 2024 GAAP EPS $0.83 Beats $0.80 Estimate, Sales $98.507M Miss $100.039M Estimate

Oppenheimer analyst Michael Wiederhorn maintains Community Health Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYH#NYSE">CYH</a>) with a Outperform and lowers the price target from $5.5 to $4.5.

Price Target

Analyst Ratings

Oppenheimer Maintains Outperform on Community Health Sys, Lowers Price Target to $4.5

Worksport Signals Undervalued Status, Eyes Major 2024 Growth
West Seneca, New York 04-25-2024 - Worksport Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKSP#NASDAQ">WKSP</a>, WKSPW)))), a U.S.-based manufacturer dedicated to developing innovative hybrid and clean energy solutions in light truck, overlanding, and global consumer goods markets, today released a memo to shareholders, iterating management's outlook on maximizing shareholder value and setting the stage for a transformative year in projected growth for 2024, on all fronts.&nbsp;
"As we steer through a pivotal phase at Worksport, our direction is clear and aimed at reinforcing our position as a leader in truck accessories and sustainable automotive solutions," said Steven Rossi, CEO &amp; President of Worksport. "With our focus on delivering innovative products that cater to the booming pickup truck, overlanding, and off-roading communities, we have just begun capturing our share of these significant market segments."
Corporate Valuation and Growth Outlook:
●&nbsp;Undervalued Stock Potential: With over 150 registered and pending patents and trademarks, a state-of-the-art facility valued at over $9.2 million-exceeding our current market cap-and advanced manufacturing equipment valued at more than $7 million, it is our belief that Worksport stock is significantly undervalued.
●&nbsp;Year-end sales for 2024 are expected to significantly increase from the previous year, primarily driven by Worksport's U.S.-made hard covers along with highly anticipated green-energy products coming this summer. Having already generated significant press and industry interest, the market introduction of the SOLIS solar cover and the COR portable energy storage system in the months ahead is expected to exponentially boost growth potential and substantially enhance shareholder returns.
Strategic Inventory and Production Milestones:
●&nbsp;Robust Inventory and Supply Chain Stability: With a robust balance of inventory to produce new products, a significant revenue growth opportunity is present, and is being met by strong demand for the Company's Made in America hard-covers. The Company is confident in its ability to produce significant volumes and capitalize on increasing demand without delay.
●&nbsp;B2C Sales Momentum: Direct-to-consumer sales campaigns initiated in March 2024 have already led to an uptick in sales, with sales figures from April 2024 already surpassing internal projections, indicating robust consumer demand and market acceptance.
●&nbsp;Accelerated B2B Engagements: An overwhelmingly positive reception from major U.S. business customers, including initial purchase orders from three leading players, has accelerated the Company's B2B pipeline, while marking a significant vote of confidence in Worksport's technology and business model.
Innovation and Market Expansion:
●&nbsp;First-to-Market Solar Truck Bed Cover: Finalized after extensive engineering and prototyping, the patented SOLIS cover is set for its market debut this summer. As a pioneer in the solar technology space, capturing even 5% of the U.S. market translates to significant revenue potential, potentially exceeding $300 million annually from the solar cover line alone. The SOLIS Solar Truck Bed Cover will be among the very first to market and will be available for all major makes and models. The Company has received copious interest from the media, industry partners, and consumers for this forthcoming innovation.
●&nbsp;COR Solid State Power Generator Launch: Complementing the SOLIS cover, the patent pending COR battery system is nearing the end of its prototyping phase. With each SOLIS unit sold, a COR unit stands as its perfect counterpart, enhancing utility and customer value. Alpha units of the COR system are expected to be available by this summer with strong interest from US Government Agencies &amp; Major Retailers.
●&nbsp;Groundbreaking Heat Pump Technology: Additionally, Worksport subsidiary, Terravis Energy, Inc., is on the brink of completing an innovative residential heat pump that surpasses existing technological standards by up to 40%. With the global heat pump market projected to grow at a CAGR of 8.5%, reaching $142.4 Billion by 2030, this development has garnered significant interest from conglomerate companies and governments worldwide.
Grants and Intellectual Property:
●&nbsp;Many active grant applications: Currently Worksport is actively pursuing several multi-million-dollar grants to further support the business, research and development efforts, and sales efforts. Worksport will be excited to share updates in the coming months regarding some of these applications.
●&nbsp;Expanding IP Portfolio: The strength of Worksport's intellectual property portfolio continues to further solidify our market position and innovation capacity, with new additions to the portfolio every quarter for the last year.
Despite a stock price that does not reflect our true value, the company believes 2024 is set to be an inflection point for Worksport that solidifies our position as a U.S-based manufacturer dedicated to developing innovative hybrid and clean energy solutions in the light truck, overlanding, and global consumer goods markets.

Guidance

WKSP

Worksport Issues Company Memo, Signals Undervalued Status, Eyes Major 2024 Growth

Visa to streamline access to select services via the AWS partner network for its cloud-native fintech, financial institution, and enterprise clients
Visa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>), a world leader in global digital payments, announced today it has joined the AWS Partner Network (APN), a global community that leverages AWS technologies, programs, expertise, and tools to build solutions and services for customers. Visa's presence in the APN will help enable its partners and clients, including cloud-native fintechs, to access and integrate select Visa services more efficiently.
Global Payments Simplified
Visa is committed to making transactions faster, easier and more secure for all players in the payments ecosystem. Visa will make select payment services available in the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Faws.amazon.com%2Fmarketplace%2F&amp;esheet=53956845&amp;newsitemid=20240425648724&amp;lan=en-US&amp;anchor=AWS+Marketplace&amp;index=1&amp;md5=333e4db72dfb5e8bdd8f833c37b5920f">AWS Marketplace</a>, which has more than 300,000 global customers and thousands of software listings.
By making its services available in AWS, Visa is meeting its clients where they are. One of the first services to be available is <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fusa.visa.com%2Fsolutions%2Fvisa-cross-border-solutions.html&amp;esheet=53956845&amp;newsitemid=20240425648724&amp;lan=en-US&amp;anchor=Visa+Cross-Border+Solutions&amp;index=2&amp;md5=14c2ac3b9e9b2d4bb4fea523d008d1b8">Visa Cross-Border Solutions</a>, which assists in streamlining the process of sending and receiving money globally and holding multiple currencies. This strategic positioning will allow Visa's clients to integrate solutions like Visa Cross-Border Solutions into their business operations - eliminating the need for them to step out of their established platforms.
"Visa is dedicated to better serving our clients in cloud environments, which is why we're excited to bring Visa Cross-Border Solutions to the AWS Marketplace," said Vanessa Colella, Global Head of Innovation and Digital Partnerships, Visa. "We aim to make our solutions readily accessible and available for customers to easily integrate across diverse platforms. This is a step further in our broader commitment to reduce challenges for financial institutions and enterprises."
Cloud-Based Connectivity
Through AWS, Visa plans to bring more of its products to clients operating in the cloud. Companies wanting to process payments through AWS on <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcorporate.visa.com%2Fen%2Fabout-visa%2Fvisanet.html&amp;esheet=53956845&amp;newsitemid=20240425648724&amp;lan=en-US&amp;anchor=VisaNet&amp;index=3&amp;md5=65924159146fed437711573c9cea57ba">VisaNet</a>, Visa's global processing network, can already establish secure AWS Privatelink connectivity with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fusa.visa.com%2Fproducts%2Fvisa-cloud-connect.html&amp;esheet=53956845&amp;newsitemid=20240425648724&amp;lan=en-US&amp;anchor=Visa+Cloud+Connect&amp;index=4&amp;md5=71e9dc0a0f8776cd99448f1c6aa44615">Visa Cloud Connect</a>.
Cloud-native fintechs, financial institutions, and enterprises have found using cloud services can help accelerate service deployment and customer adoption. It can also contribute to lowering costs associated with local data centers, implementing specialized hardware like physical routers, and payment hardware security modules (HSMs).
"As a cloud-native card issuer and processor, and one of the first issuer processors in Europe to connect to the Visa Cloud Connect endpoint in the EU, we believe the enablement of Visa services through AWS is a gamechanger," said Merusha Naidu, Global Head of Partnerships, Paymentology. "This partnership paves the way for enhanced digital payment solutions, providing startups with the tools they need to innovate and thrive in today's fast-paced landscape."
Empowering Startups with Fintech Solutions
Visa is also proud to announce that it is now part of <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Faws.amazon.com%2Factivate%2Factivate-landing%2F&amp;esheet=53956845&amp;newsitemid=20240425648724&amp;lan=en-US&amp;anchor=AWS+Activate&amp;index=5&amp;md5=cc43861259d18dfd725af01cdf48c54e">AWS Activate</a>, AWS's flagship startup program. Fintech clients enrolled in the Visa <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpartner.visa.com%2Fsite%2Fprograms%2Ffintech-program.html&amp;esheet=53956845&amp;newsitemid=20240425648724&amp;lan=en-US&amp;anchor=Fintech+Fast+Track+program&amp;index=6&amp;md5=c9fbd246968dcbc8412c3ff3e7109b07">Fintech Fast Track program</a>, and verified by AWS as eligible, can receive up to $100,000 in AWS Activate credits to help jumpstart their growth and reduce their time to market.
"We are excited to support the expansion of digital payments, banking, and embedded finance capabilities to enterprises and fintech startups building their applications on AWS," said Howard Wright, VP and Global Head of Startups at AWS. "We are looking forward to working with Visa to help make financial apps in the cloud more accessible, faster, secure, and easier to use."
Many startups running on AWS have already benefited from Visa programs like <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpartner.visa.com%2Fsite%2Fprograms%2Fvisa-ready.html&amp;esheet=53956845&amp;newsitemid=20240425648724&amp;lan=en-US&amp;anchor=Visa+Ready&amp;index=7&amp;md5=476237ec92741dc666d4fd2e8177e583">Visa Ready</a> and Fintech Fast Track.

AMZN

Visa Joins AWS Partner Network To Help Simplify Global Digital Payments

Guidance
Hess Midstream continues to target at least&nbsp;5%&nbsp;annual distribution growth per Class A share through 2026 from this new higher level and continues to prioritize financial strength with a long-term leverage target of 3x Adjusted EBITDA. For 2025 and 2026, Hess Midstream continues to expect organic throughput volume growth across all systems relative to 2024 volume&nbsp;guidance.
Hess Midstream is reaffirming its full year 2024&nbsp;guidance&nbsp;as follows:
<table cellspacing="0">
<tbody>
<tr>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="2" rowspan="1">
Year Ending
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="2" rowspan="1">
December 31, 2024
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="2" rowspan="1">
(Unaudited)
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Financials (in millions)
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Net income
</td>
<td colspan="1" rowspan="1">
$
</td>
<td colspan="1" rowspan="1">
670 - 720
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Adjusted EBITDA
</td>
<td colspan="1" rowspan="1">
$
</td>
<td colspan="1" rowspan="1">
1,125 - 1,175
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Capital expenditures
</td>
<td colspan="1" rowspan="1">
$
</td>
<td colspan="1" rowspan="1">
250 - 275
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Adjusted free cash flow
</td>
<td colspan="1" rowspan="1">
$
</td>
<td colspan="1" rowspan="1">
685 - 735
</td>
</tr>
</tbody>
</table>

HESM

Hess Midstream Reaffirms 2024 Guidance For Net Income Of $670M - $720M, Adjusted EBITDA Of $1.125B – $1.175B And Adjusted Free Cash Flow Of $685M - $735M; Continues To Target At Least 5% Annual Distribution Growth Per Class A Share Through 2026

2024&nbsp;Guidance&nbsp;Remains Unchanged
<ul>
<li>2024 Full-year average production of 35,500-39,000 boepd, as announced on February 21, 2024</li>
<li>Fully-funded 2024 organic capital expenditures program of&nbsp;$150-200 million to drill 35-45 gross wells (including 5-10 gross exploration wells and 30-35 gross appraisal and development wells)</li>
</ul>

Commodities

Markets

General

GPRK

Geopark Reports 1Q 2024 Average Oil And Gas Production Of 35,473 Boe/Day

<ul>
<li>Upadacitinib demonstrated superiority versus dupilumab in primary endpoint of simultaneous achievement of near complete skin clearance (EASI 90) and no to little itch (WP-NRS 0/1) at Week 161</li>
<li>LEVEL UP, a Phase 3b/4 head-to-head study, compared upadacitinib to dupilumab for the treatment of adult and adolescent patients with moderate-to-severe atopic dermatitis who had inadequate response to systemic therapy or when use of those therapies was inadvisable1</li>
<li>The safety profile of upadacitinib was consistent with the profile in previous atopic dermatitis studies with no new safety signals identified during the 16-week period1,2</li>
</ul>
NORTH CHICAGO, Ill., April 25, 2024 /PRNewswire/ --&nbsp;AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) today announced positive topline results from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Phase 3b/4&nbsp;study that evaluated the efficacy and safety of upadacitinib (RINVOQ&#xAE;, 15 mg once daily starting dose and dose-adjusted based on clinical response) versus dupilumab (DUPIXENT&#xAE;, per its labeled dose) in adults and adolescents (≥12 years of age) with moderate-to-severe atopic dermatitis (AD) who had an inadequate response to systemic therapy or when use of those therapies was inadvisable.
"Even while receiving conventional treatments, many patients with atopic dermatitis still continue to live with&nbsp;significant itch&nbsp;and inflammatory skin symptoms that can profoundly impact their everyday lives," said&nbsp;Roopal Thakkar, M.D., senior vice president, chief medical officer, global therapeutics, AbbVie. "Results from this study show that patients with moderate-to-severe atopic dermatitis can strive for both little to no itch and clearer skin."
In the LEVEL UP study,&nbsp;upadacitinib showed superior efficacy versus dupilumab in the primary endpoint, demonstrating that a significantly higher proportion of patients simultaneously achieved both a 90% or greater reduction in Eczema Area and Severity Index (EASI 90) and a Worst Pruritus Numerical Rating Scale of 0 or 1 (WP-NRS 0/1) at Week 16 [(19.9% vs 8.9% for upadacitinib and dupilumab respectively, p&lt;0.0001)].1
The EASI is a clinically validated measure used to assess the severity and extent of atopic dermatitis, while the WP-NRS is an assessment tool that patients use to report the intensity of their pruritus daily (with 0 being 'no itch' and 10 being the 'worst imaginable itch').
Upadacitinib also showed superiority versus dupilumab for all ranked secondary endpoints, including the rapid onset of achieving near complete skin clearance and no to little itch.&nbsp;For the first two ranked secondary endpoints, the study showed that&nbsp;a significantly higher proportion of patients treated with upadacitinib:
<ul>
<li>Achieved EASI 90 at Week 16 [(40.8% vs 22.5%, p&lt;0.0001)].1</li>
<li>Achieved a WP-NRS of 0/1 at Week 16 [(30.2% vs 15.5%, p&lt;0.0001)].1,a</li>
</ul>
AbbVie plans to present results from the LEVEL UP study at a future medical congress.
The LEVEL UP study is the first head-to-head trial in atopic dermatitis assessing upadacitinib at a starting&nbsp;dose of 15 mg daily versus dupilumab at its labeled dose. Upadacitinib was initiated in adults and adolescents (≥12 years of age, weighing at least 40 kg) at 15 mg once daily (QD) and dose-escalated to 30 mg QD based on clinical response. Dupilumab was initiated at 600 mg, followed by 300 mg every other week (Q2W) in adults and adolescents weighing ≥60 kg; adolescents weighing less than 60 kg received an initial dose of 400 mg, followed by 200 mg Q2W.1
"Too many patients are still not achieving optimal disease control in atopic dermatitis despite taking steps to manage their condition," said&nbsp;Jonathan Silverberg, M.D., Ph.D., MPH, professor of dermatology and director of clinical research at the George Washington University School of Medicine and Health Sciences. "Results from the LEVEL UP study highlight how treatment options such as upadacitinib can achieve high treatment goals in atopic dermatitis with combined measures of EASI 90 and NRS 0/1, not just itch resolution or just skin clearance."
The observed safety profile for upadacitinib in LEVEL UP was consistent with that observed in previous upadacitinib atopic dermatitis clinical studies.1,2 No new safety signals were identified during the study period.1 In Period 1, the most common adverse events&nbsp;(AE) reported were nasopharyngitis&nbsp;for both the upadacitinib and dupilumab group.1 The rate of serious AEs (0.9%) was the same for both upadacitinib and dupilumab. There was one serious infection reported in the dupilumab group and none in the upadacitinib group.1&nbsp;No malignancies, adjudicated major adverse cardiac events, adjudicated venous thromboembolic events (VTEs)&nbsp;or treatment-emergent deaths were reported in either treatment group.1
[a]&nbsp;This endpoint was evaluated among patients with a baseline WP-NRS &gt;1.
About Atopic Dermatitis&nbsp;

Biotech

ABBV

AbbVie New Data Show RINVOQ Demonstrated Superiority Versus DUPIXENT Across Primary And All Secondary Endpoints In An Open-Label Head-To-Head Atopic Dermatitis Study; Achieved Both A 90% Or Greater Reduction In Eczema Area And Severity Index And A Worst Pruritus Numerical Rating Scale Of 0 Or 1 At Week 16

West Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTBA#NASDAQ">WTBA</a>) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate of $0.27 by 29.63 percent. This is a 25.53 percent decrease over earnings of $0.47 per share from the same period last year. The company reported quarterly sales of $19.049 million which beat the analyst consensus estimate of $18.890 million by 0.84 percent. This is a 12.02 percent decrease over sales of $21.652 million the same period last year.

WTBA

West Bancorp Q1 2024 GAAP EPS $0.35 Beats $0.27 Estimate, Sales $19.049M Beat $18.890M Estimate

ShareCap calls on the Board to initiate a strategic alternatives process that, among the alternatives, reconsiders Future Pak&#39;s offer.

VNDA

Vanda Pharmaceuticals Shareholder ShareCap Says Company Board Must Explore Strategic Alternatives

T-Mobile US, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) is set to release earnings results for its first quarter, after the <a href="https://www.benzinga.com/quote/TMUS/earnings">closing bell on April 25, 2024.</a>
Analysts expect the Bellevue, Washington-based company to report quarterly earnings at $1.87 per share, up from $1.58 per share in the year-ago period. T-Mobile US is projected to post revenue of $19.81 billion (roughly the same as the year-earlier quarter, per data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>).
T-Mobile recently announced $163 Million in completed network upgrades for Arkansas.
With the recent buzz around T-Mobile US, some investors may be eyeing potential gains from the company's dividends, too. T-Mobile US currently offers an annual dividend yield of 1.58% — a quarterly dividend amount of 65 cents per share ($2.60 a year).
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $378,927 or around 2,308 shares. For a more modest $100 per month or $1,200 per year, you would need $75,851 or around 462 shares.
Read This: <a href="https://www.benzinga.com/news/24/04/38402061/jim-cramer-says-this-energy-stock-is-terrific-calls-caseys-general-stores-a-winner">Jim Cramer Says This Energy Stock Is &#8216;Terrific,&#8217; Calls Casey&#8217;s General Stores A &#8216;Winner&#8217;</a>
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($2.60 in this case). So, $6,000 / $2.60 = 2,308 ($500 per month), and $1,200 / $2.60 = 462 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
TMUS Price Action: Shares of T-Mobile US rose 0.6% to close at $164.18 on Wednesday.
Read More: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/04/38405528/over-1m-bet-on-citi-trends-check-out-these-3-stocks-insiders-are-buying">Over $1M Bet On Citi Trends? Check Out These 3 Stocks Insiders Are Buy</a><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/04/38405528/over-1m-bet-on-citi-trends-check-out-these-3-stocks-insiders-are-buying">ing</a>
Image: Shutterstock

Long Ideas

Trading Ideas

TMUS

How To Earn $500 A Month From T-Mobile US Stock Ahead Of Q1 Earnings Report

ROIV

Roivant And Kinevant Sciences Complete Enrollment In RESOLVE-Lung Phase 2 Study Evaluating Namilumab For Chronic Pulmonary Sarcoidosis

Standard BioTools Expects To Achieve $45M-$50M In Annualized Operating Expense Savings In Fiscal 2025

Telsey Advisory Group analyst Sarang Vora maintains Coursera (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COUR#NYSE">COUR</a>) with a Outperform and maintains $25 price target.

COUR

Telsey Advisory Group Maintains Outperform on Coursera, Maintains $25 Price Target

Health Care

XOMA

Xoma Earns $9M As FDA Grants Accelerated Approval To Day One's Ojemda (Tovorafenib) For Relapsed Or Refractory BRAF-Altered Pediatric Low-grade Glioma

<a href="https://www.theinformation.com/articles/bytedance-exploring-scenarios-for-selling-tiktok-without-algorithm" title="https://www.theinformation.com/articles/bytedance-exploring-scenarios-for-selling-tiktok-without-algorithm">https://www.theinformation.com/articles/bytedance-exploring-scenarios-for-selling-tiktok-without-algorithm</a>

Asset Sales

GOOG

GOOGL

PINS

SNAP

'ByteDance Exploring Scenarios For Selling TikTok Without Algorithm' - The Information

As part of the investment, Sopris Capital has purchased 2.906 million Class A common shares and is now one of Bitcoin Depot&#39;s largest independent shareholders.

Bitcoin Depot Reveals Strategic Investment From Sopris Capital

<h3>Gainers</h3>
<ul>
<li>Grove Collaborative Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GROV#NYSE">GROV</a>) stock rose 8.6% to $1.65 during Thursday's pre-market session. The company's market cap stands at $63.0 million. </li>
<li>Serve Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>) stock moved upwards by 7.83% to $3.04. </li>
<li>Connexa Sports Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YYAI#NASDAQ">YYAI</a>) stock moved upwards by 7.26% to $0.95. The market value of their outstanding shares is at $175.1 million. </li>
<li>Visionary Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GV#NASDAQ">GV</a>) stock rose 7.06% to $0.16. The market value of their outstanding shares is at $8.2 million. </li>
<li>Mobileye Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) stock moved upwards by 6.87% to $33.26. The company's market cap stands at $26.8 billion. As per the press release, Q1 earnings came out today. </li>
<li>Big Lots (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIG#NYSE">BIG</a>) shares increased by 4.98% to $3.58. The market value of their outstanding shares is at $105.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Jakks Pacific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAKK#NASDAQ">JAKK</a>) shares declined by 10.2% to $21.06 during Thursday's pre-market session. The company's market cap stands at $227.4 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>EpicQuest Education Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EEIQ#NASDAQ">EEIQ</a>) shares fell 9.46% to $0.75. The market value of their outstanding shares is at $9.2 million. </li>
<li>MarineMax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HZO#NYSE">HZO</a>) shares fell 9.13% to $24.7. The market value of their outstanding shares is at $550.7 million. As per the press release, Q2 earnings came out today. </li>
<li>Amesite (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMST#NASDAQ">AMST</a>) stock declined by 8.96% to $3.05. The market value of their outstanding shares is at $7.7 million. </li>
<li>Massimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAMO#NASDAQ">MAMO</a>) stock fell 6.09% to $4.17. The company's market cap stands at $172.2 million. </li>
<li>Genius Gr (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GNS#AMEX">GNS</a>) shares declined by 5.02% to $0.4. The company's market cap stands at $38.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AMST

EEIQ

GROV

JAKK

MAMO

MBLY

SERV

Connexa Sports Technologies Inc. - Common Stock

YYAI

12 Consumer Discretionary Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Processa Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) shares moved upwards by 31.2% to $2.12 during Thursday's pre-market session. The company's market cap stands at $6.0 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock rose 23.04% to $2.83. The company's market cap stands at $3.7 million. </li>
<li>Compass Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPX#NASDAQ">CMPX</a>) shares rose 21.62% to $1.8. The market value of their outstanding shares is at $247.6 million. </li>
<li>Virax Biolabs Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAX#NASDAQ">VRAX</a>) shares increased by 19.37% to $0.79. The company's market cap stands at $1.8 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) shares increased by 13.84% to $0.29. The company's market cap stands at $1.9 million. </li>
<li>Can Fite Biofarma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CANF#AMEX">CANF</a>) stock moved upwards by 12.37% to $2.18. The company's market cap stands at $10.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) stock decreased by 10.5% to $0.83 during Thursday's pre-market session. </li>
<li>Vaccinex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCNX#NASDAQ">VCNX</a>) shares declined by 8.1% to $4.6. The company's market cap stands at $7.2 million. </li>
<li>SenesTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>) stock fell 8.04% to $0.7. The company's market cap stands at $3.6 million. </li>
<li>Pluri (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUR#NASDAQ">PLUR</a>) stock decreased by 7.27% to $4.72. The company's market cap stands at $24.6 million. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) stock fell 7.02% to $1.59. The market value of their outstanding shares is at $6.4 million. </li>
<li>Heart Test Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSCS#NASDAQ">HSCS</a>) shares declined by 6.86% to $0.1. The market value of their outstanding shares is at $6.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADIL

CANF

CMPX

CYCC

HSCS

NUWE

PCSA

PLUR

SBFM

SNES

VCNX

VRAX

12 Health Care Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Intelligent Living (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILAG#NASDAQ">ILAG</a>) shares rose 56.6% to $0.85 during Thursday's pre-market session. The market value of their outstanding shares is at $15.2 million. </li>
<li>Ultralife (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULBI#NASDAQ">ULBI</a>) stock rose 17.27% to $10.24. The company's market cap stands at $168.4 million. The company's, Q1 earnings came out today. </li>
<li>P.A.M. Transportation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTSI#NASDAQ">PTSI</a>) stock increased by 12.17% to $16.31. The company's market cap stands at $359.3 million. </li>
<li>TransUnion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRU#NYSE">TRU</a>) stock moved upwards by 12.11% to $77.0. The company's market cap stands at $14.9 billion. As per the news, the Q1 earnings report came out today. </li>
<li>Nauticus Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KITT#NASDAQ">KITT</a>) stock rose 8.21% to $0.21. The company's market cap stands at $12.8 million. </li>
<li>SES AI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SES#NYSE">SES</a>) shares moved upwards by 7.93% to $1.36. The company's market cap stands at $482.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Lichen China (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LICN#NASDAQ">LICN</a>) shares decreased by 8.4% to $0.92 during Thursday's pre-market session. The market value of their outstanding shares is at $25.0 million. </li>
<li>ESGL Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESGL#NASDAQ">ESGL</a>) stock fell 8.13% to $0.58. The company's market cap stands at $13.3 million. </li>
<li>Textron (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TXT#NYSE">TXT</a>) stock decreased by 7.04% to $87.4. The market value of their outstanding shares is at $16.8 billion. As per the news, the Q1 earnings report came out today. </li>
<li>Northann (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NCL#AMEX">NCL</a>) stock decreased by 6.38% to $0.5. The market value of their outstanding shares is at $10.5 million. </li>
<li>Shimmick (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHIM#NASDAQ">SHIM</a>) stock declined by 6.34% to $2.81. The company's market cap stands at $71.8 million. </li>
<li>Earlyworks Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELWS#NASDAQ">ELWS</a>) shares fell 5.59% to $0.58. The market value of their outstanding shares is at $8.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ELWS

ESGL

ILAG

KITT

LICN

Nuveen Insured California Premium Fund Ii

PTSI

SHIM

ULBI

12 Industrials Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>ReAlpha Tech Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRE#NASDAQ">AIRE</a>) stock rose 48.3% to $1.72 during Thursday's pre-market session. The company's market cap stands at $75.8 million. As per the press release, Q1 earnings came out 4 days ago. </li>
<li>Nano Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NA#NASDAQ">NA</a>) stock increased by 10.58% to $0.43. The market value of their outstanding shares is at $17.7 million. </li>
<li>Focus Universal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCUV#NASDAQ">FCUV</a>) stock increased by 10.53% to $0.31. The market value of their outstanding shares is at $20.0 million. </li>
<li>Ultra Clean Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCTT#NASDAQ">UCTT</a>) stock increased by 10.28% to $44.4. The company's market cap stands at $1.9 billion. </li>
<li>Impinj (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PI#NASDAQ">PI</a>) stock moved upwards by 9.99% to $133.0. The market value of their outstanding shares is at $3.6 billion. As per the press release, Q1 earnings came out yesterday. </li>
<li>Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) stock moved upwards by 9.13% to $109.9. The market value of their outstanding shares is at $16.8 billion. As per the press release, Q1 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Alpha Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATGL#NASDAQ">ATGL</a>) shares decreased by 11.5% to $2.3 during Thursday's pre-market session. The company's market cap stands at $35.1 million. </li>
<li>IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) stock decreased by 8.78% to $167.95. The company's market cap stands at $153.9 billion. As per the press release, Q1 earnings came out yesterday. </li>
<li>NextTrip (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRP#NASDAQ">NTRP</a>) stock declined by 8.76% to $2.71. The company's market cap stands at $3.6 million. </li>
<li>Ostin Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OST#NASDAQ">OST</a>) stock declined by 7.77% to $0.42. The market value of their outstanding shares is at $7.1 million. </li>
<li>BIT Mining (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTCM#NYSE">BTCM</a>) stock decreased by 7.26% to $2.94. The company's market cap stands at $32.6 million. </li>
<li>Brand Engagement Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNAI#NASDAQ">BNAI</a>) shares decreased by 7.24% to $3.46. The market value of their outstanding shares is at $115.2 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.